Citadel Advisors
VNRX icon

Citadel Advisors’s VolitionRx Ltd VNRX Stock Holding History

Citadel Advisors’s Portfolio VNRX Stock Details VNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5
Closed -$60 – 15462
2024
Q3 		$60 Sell
5
-10
-67% -$129 ﹤0.01% 14099
2024
Q2 		$182 Buy
+15
New +$220 ﹤0.01% 14075
2023
Q3 		– Sell
-430
Closed -$12K – 15200
2023
Q2 		$12K Sell
430
-480
-53% -$15.8K ﹤0.01% 13107
2023
Q1 		$34.8K Buy
910
+325
+56% +$13.6K ﹤0.01% 12593
2022
Q4 		$28.4K Buy
+585
New +$22.7K ﹤0.01% 12801
2022
Q3 		– Sell
-665
Closed -$27K – 13686
2022
Q2 		$27K Buy
+665
New +$33.5K ﹤0.01% 12282
2022
Q1 		– Sell
-625
Closed -$39K – 14655
2021
Q4 		$39K Sell
625
-120
-16% -$8.19K ﹤0.01% 13385
2021
Q3 		$46K Sell
745
-160
-18% -$10.1K ﹤0.01% 13415
2021
Q2 		$60K Buy
+905
New +$61.2K ﹤0.01% 13252

Other funds holding VNRX

LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Citadel Advisors's VNRX Position: Q1 2026 in Review

Citadel Advisors sold out of VolitionRx Ltd (VNRX) in Q1 2026, closing a stake of 8,387 shares — an estimated $42.9K sold.

Citadel Advisors first reported a position in VNRX in Q2 2020 and held it in 14 quarters. The position peaked at $224K in Q3 2025. 31 funds tracked by Wall St. Rank hold VNRX as of Q1 2026.

  • Citadel Advisors reported no remaining VolitionRx Ltd position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 8,387 VolitionRx Ltd shares in Q1 2026, an estimated $42.9K.
  • Citadel Advisors first reported a position in VolitionRx Ltd in Q2 2020 and held it in 14 quarters.
  • Citadel Advisors's VolitionRx Ltd position peaked at $224K in Q3 2025.
  • 31 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.